Ji Fubo, Zhang Jianjuan, Mao Liping, Tan Yaqi, Ye Meihua, He Xianglei, Zhao Yongzhi, Liu Jiaxin, Zhang Yan, Zhang Nachuan, Shi Jiong, Yan Jianing, Cai Xiujun, Zhao Bin, Jin Jianping, Xu Pinglong, Roessler Stephanie, Zheng Xin, Ji Junfang
The MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, 310058, China.
Center for Life Sciences, Shaoxing Institute, Zhejiang University, Shaoxing, Zhejiang, 321000, China.
Nat Commun. 2025 Jan 2;16(1):50. doi: 10.1038/s41467-024-55745-2.
Roles of liver-specific genes (LSGs) in tumor initiation and progression are rarely explored in hepatocellular carcinoma (HCC). Here we show that LSGs are generally downregulated in HCC tumor tissues compared to non-HCC liver tissues, and low-LSG HCCs show poor prognosis and the activated c-Myc pathway. Among the c-Myc- and patient prognosis-associated LSGs, PGRMC1 significantly blocks c-Myc-induced orthotopic HCC formation. The role of PGRMC1 depends on its localization to the endoplasmic reticulum (ER) membrane, where PGRMC1 interacts with PERK through their ER luminal domains. This interaction in turn activates PERK in an ER stress-independent manner, which phosphorylates eIF2α and consequently inhibits c-Myc protein translation. In HCC patients, PGRMC1 level is significantly reduced in tumor tissues and negatively associated with the c-Myc signature. Patients with low-PGRMC1 in their tumors have poor prognosis. Collectively, deregulated LSGs in HCC are associated with the c-Myc pathway activation and PGRMC1 blocks c-Myc-induced hepatic carcinogenesis through promoting ER stress-independent PERK activation.
肝细胞癌(HCC)中肝脏特异性基因(LSGs)在肿瘤起始和进展中的作用鲜有研究。在此我们表明,与非HCC肝脏组织相比,LSGs在HCC肿瘤组织中普遍下调,低LSG的HCC预后较差且c-Myc通路激活。在与c-Myc和患者预后相关的LSGs中,PGRMC1显著阻断c-Myc诱导的原位HCC形成。PGRMC1的作用取决于其在内质网(ER)膜上的定位,在那里PGRMC1通过其ER腔结构域与PERK相互作用。这种相互作用进而以不依赖ER应激的方式激活PERK,使eIF2α磷酸化,从而抑制c-Myc蛋白翻译。在HCC患者中,肿瘤组织中PGRMC1水平显著降低,且与c-Myc特征呈负相关。肿瘤中PGRMC1水平低的患者预后较差。总体而言,HCC中失调的LSGs与c-Myc通路激活相关,且PGRMC1通过促进不依赖ER应激的PERK激活来阻断c-Myc诱导的肝癌发生。